Clinical Trial: Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma

U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07276737) titled 'Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma' on Nov. 29.

Brief Summary: Evaluation of the efficacy and safety of Thiotepa combined with Cyclophosphamide and Busulfan as conditioning regimen before allo-HSCT for the treatment of NK/T cell lymphoma

Study Start Date: Dec. 30

Study Type: INTERVENTIONAL

Condition: NK T-Cell Lymphoma

Intervention: DRUG: Thiotepa

The enrolled patients began the pre-treatment on day d-9. The pre-treatment regimen was as follows: Thiotepa 5mg/kg/d, from -9d to -8d (2d); Cycl...